Inventor · disambiguated record
Seth Ettenberg
Also filed as: ETTENBERG SETH · ETTENBERG SETH ALEXANDER
12 granted patents·27 pending applications·98 citations·filing 2002–2024
90Inventor score
Top patents by PatentIndex Score
39 records- 0191US8735551B2Antibodies for epidermal growth factor receptor 3 (HER3)GARNER ANDREW PAUL·Filed 2011·Granted May 27, 2014·43 cites·31 claims
- 0288US9290573B2Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Mar 22, 2016·16 cites·9 claims
- 0386US9415118B2Antibody drug conjugatesBATT JULIE LYNN·Filed 2014·Granted Aug 16, 2016·9 cites·24 claims
- 0484US9192663B2Antibodies for epidermal growth factor receptor 3 (HER3)NOVARTIS AG·Filed 2012·Granted Nov 24, 2015·8 cites·8 claims
- 0579US9498532B2Antibody drug conjugatesBATT DAVID BRYANT·Filed 2014·Granted Nov 22, 2016·8 cites·32 claims
- 0678US10077317B2Antibodies for epidermal growth factor receptor 3 (HER3)NOVARTIS AG·Filed 2014·Granted Sep 18, 2018·3 cites·3 claims
- 0778US9120855B2Biologic compounds directed against death receptor 5CROMIE KAREN·Filed 2011·Granted Sep 1, 2015·7 cites·17 claims
- 0869US9428583B2Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Aug 30, 2016·1 cites·52 claims
- 0968US8673306B2Compositions and methods of use for antibodies of dickkopf-1SHULOK JANINE·Filed 2007·Granted Mar 18, 2014·2 cites·11 claims
- 1066US2024376442A1Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2024·Application pending·0 cites
- 1164US2021008201A1Antibodies for epidermal growth factor receptor 3 (her3)NOVARTIS AG·Filed 2020·Application pending·0 cites
- 1262US9296813B2Compositions and methods of use for antibodies of Dickkopf-1SHULOK JANINE R·Filed 2014·Granted Mar 29, 2016·1 cites·19 claims
- 1359US12077785B2Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2019·Granted Sep 3, 2024·0 cites·23 claims
- 1459US2020377603A1Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodiesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1557US2019216924A1Antibodies for epidermal growth factor receptor 3 (her3)NOVARTIS AG·Filed 2018·Application pending·0 cites
- 1655US2019194347A1Antibodies for epidermal growth factor receptor 3 (her3)NOVARTIS AG·Filed 2018·Application pending·0 cites
- 1752US2017008964A1Antibody drug conjugatesBATT DAVID BRYANT·Filed 2016·Application pending·0 cites
- 1851US2015259426A1Biologic compoundsNOVARTIS AG·Filed 2014·Application pending·0 cites
- 1950US2024390495A1Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereofSOTIO BIOTECH INC·Filed 2022·Application pending·0 cites
- 2050US2017362326A1Compositions and Methods of Use for Therapeutic Low Density Lipoprotein-related protein 6 (LRP6) AntibodiesNOVARTIS AG·Filed 2016·Application pending·0 cites
- 2150US2019345250A1Antibody drug conjugatesBATT DAVID BRYANT·Filed 2018·Application pending·0 cites
- 2249US10080800B2Antibodies for epidermal growth factor receptor 3 (HER3)NOVARTIS AG·Filed 2015·Granted Sep 25, 2018·0 cites·9 claims
- 2349US2010254980A1Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)NOVARTIS AG·Filed 2008·Application pending·0 cites
- 2448US2006003323A1Therapeutic polypeptides, nucleic acids encoding same, and methods of useALSOBROOK JOHN·Filed 2003·Application pending·0 cites
- 2548US2021340219A1Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereofSOTIO LLC·Filed 2019·Application pending·0 cites
- 2647US2004029226A1Therapeutic polypeptides, nucleic acids encoding same, and methods of useFiled 2003·Application pending·0 cites
- 2747US2014341901A1Compositions and methods of use for antibodies of dickkopf-1SHULOK JANINE R·Filed 2014·Application pending·0 cites
- 2847US2021261646A1Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereofSOTIO LLC·Filed 2019·Application pending·0 cites
- 2946US2006084054A1Novel proteins and nucleic acids encoding sameALSOBROOK JOHN·Filed 2003·Application pending·0 cites
- 3044US2004067882A1Therapeutic polypeptides, nucleic acids encoding same, and methods of useFiled 2002·Application pending·0 cites
- 3142US2007098715A1Antibodies against the tenascin major antigensETTENBERG SETH·Filed 2006·Application pending·0 cites
- 3241US2019112349A1Modified chimeric receptors and uses thereof in immune therapyUNUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3340US2013273029A1Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3NOVARTIS AG·Filed 2012·Application pending·0 cites
- 3439US2005244868A1Ten-M3 polypeptides and polynucleotides and their methods of useKEKUDA RAMESH·Filed 2005·Application pending·0 cites
- 3538US2017106095A1Antibody drug conjugatesBATT DAVID BRYANT·Filed 2016·Application pending·0 cites
- 3637US2019105348A1Chimeric receptors and uses thereof in immune therapyUNUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3736US2019284298A1Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatmentUNUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3836US2014056912A1Methods of treating squamous cell carcinomaETTENBERG SETH ALEXANDER·Filed 2012·Application pending·0 cites
- 3935US2019381171A1Co-use of anti-bcma antibody and antibody-coupled t cell receptor (actr) in cancer therapy and b cell disordersUNUM THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Seth Ettenberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →